Condition: Facial Rosacea · Sponsor: Zydus Worldwide DMCC
To evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Zydus Worldwide DMCC) and Soolantra® (ivermectin) cream, 1% (Galderma Laboratories, L.P.) in the treatment of moderate to severe facial papulopustular rosacea. To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of moderate to severe facial rosacea.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Zydus Worldwide DMCC | Brandon, Florida, United States | — |
| Zydus Worldwide DMCC | Fort Lauderdale, Florida, United States | — |
| Zydus Worldwide DMCC | Miami, Florida, United States | — |
| Zydus Worldwide DMCC | Miramar, Florida, United States | — |
| Zydus Worldwide DMCC | Tampa, Florida, United States | — |
| Zydus Worldwide DMCC | Saginaw, Michigan, United States | — |
| Zydus Worldwide DMCC | High Point, North Carolina, United States | — |
| Zydus Worldwide DMCC | Sugarloaf, Pennsylvania, United States | — |
| Zydus Worldwide DMCC | Upper Saint Clair, Pennsylvania, United States | — |
| Zydus Worldwide DMCC | El Paso, Texas, United States | — |
| Zydus Worldwide DMCC | El Paso, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04106726